Australia's experiment with regulated psychedelic medicine has produced encouraging results for PTSD patients, with psychiatrists reporting meaningful improvements from MDMA-assisted therapy. However, the treatment's steep price tag is preventing many people from accessing it, revealing the practical barriers in this emerging field of mental health care. The New York Times reports that while outcomes are positive, the nascent psychedelic sector still faces significant limitations around cost and availability (https://www.nytimes.com/2026/03/24/health/mdma-therapy-ptsd-psychedelic-australia.html). No specific peer-reviewed RCT details, sample sizes, or conflicts of interest were outlined in the coverage.